Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit ...
For more than 12 years, Abbott's cancer diagnostics business has helped expand access to colorectal cancer screening through ...
Abbott Presents New Esmo Data Showing 30-Percent Absolute Improvement in Sensitivity with the Whole-Genome Sequencing Oncodetect Test in Colorectal Cancer CI Oct. 22 Abbott Laboratories' Q3 Somewhat a ...
Abbott Laboratories (NYSE:ABT) received CE Mark for its Cologuard Plus colorectal cancer test under the EU In Vitro ...
Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...
Shares of Abbott Laboratories (ABT) have seen a small negative price reaction in response to a larger deal for its smaller diagnostic peer Exact Sciences Corporation (EXAS), taking place at a revenue ...
Abbott introduces whole-genome sequencing Oncodetect MRD test to detect traces of cancer during and after treatment: Abbott Park, Illinois Wednesday, October 28, 2026, 16:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results